Positive results from pivotal Phase II study of venetoclax
12 August 2015 | By Katie Sadler, Digital Content Producer, European Pharmaceutical Review
Roche have announced positive results from the Phase II M13-982 study of venetoclax, an investigational medicine developed for hard-to-treat chronic lymphocytic leukaemia.